



Corrigendum

Corrigendum to “Development and validation of LC–MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine”



[*J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.* 893–894 (2012) 92–100]

A.C. Dubbelman<sup>a,b,\*</sup>, M. Tibben<sup>b</sup>, H. Rosing<sup>b</sup>, A. Gebretensae<sup>b</sup>, L. Nan<sup>b</sup>, S.H. Gorman<sup>c</sup>, P. Robertson Jr.<sup>c</sup>, J.H.M. Schellens<sup>a,d</sup>, J.H. Beijnen<sup>b,d</sup>

<sup>a</sup> Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands

<sup>b</sup> Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands

<sup>c</sup> Department of Global Nonclinical DMPK, Teva Pharmaceutical Industries Ltd., 145 Brandywine Parkway, West Chester, PA 19380, United States

<sup>d</sup> Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Sorbonnelaan 16, 3584CA Utrecht, The Netherlands

An error in [Table 2](#) concerning the structure of bendamustine and its metabolites M3, M4 and HP2 and the internal standard BM-IS has now been corrected, by placing the bis(2-chloroethyl)amino group (or its hydrolysed derivative in case of HP2) at the 5-position of the benzimidazole moiety.

DOI of original article: <http://dx.doi.org/10.1016/j.jchromb.2012.02.039>.

\* Corresponding author at: Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands.  
E-mail address: [a.c.dubbelman@icdr.leidenuniv.nl](mailto:a.c.dubbelman@icdr.leidenuniv.nl) (A.C. Dubbelman).

**Table 2**  
Analytes with their selected mass transitions and proposed fragmentation pathways.

Compound	Transition	Proposed fragmentation
Bendamustine	358 → 228	
M3	374 → 338	
M4	344 → 186	
BM-IS	372 → 354	
HP2	322 → 304	
$\alpha$ -Dansyl-L-arginine	407 → 170	